EP Patent

EP3607969A1 — Infliximab composition containing histidine buffer system

Assigned to Hisun Biopharmaceutical Co Ltd · Expires 2020-02-12 · 6y expired

What this patent protects

Provided is a pharmaceutical composition, which comprises infliximab, a histidine buffer system, a structure protectant and a surfactant, the concentration of histidine in the histidine buffer system being approximately 1-200 mM.

USPTO Abstract

Provided is a pharmaceutical composition, which comprises infliximab, a histidine buffer system, a structure protectant and a surfactant, the concentration of histidine in the histidine buffer system being approximately 1-200 mM.

Drugs covered by this patent

Patent Metadata

Patent number
EP3607969A1
Jurisdiction
EP
Classification
—
Expires
2020-02-12
Drug substance claim
No
Drug product claim
No
Assignee
Hisun Biopharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.